|
1
|
Fratta E, Coral S, Covre A, et al: The
biology of cancer testis antigens: putative function, regulation
and therapeutic potential. Mol Oncol. 5:164–182. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
van der Bruggen P, Traversari C, Chomez P,
et al: A gene encoding an antigen recognized by cytolytic T
lymphocytes on a human melanoma. Science. 254:1643–1647. 1991.
|
|
3
|
Weber J, Salgaller M, Samid D, et al:
Expression of the MAGE-1 tumor antigen is up-regulated by the
demethylating agent 5-aza-2′-deoxycytidine. Cancer Res.
54:1766–1771. 1994.PubMed/NCBI
|
|
4
|
De Smet C, De Backer O, Faraoni I, Lurquin
C, Brasseur F and Boon T: The activation of human gene MAGE-1 in
tumor cells is correlated with genome-wide demethylation. Proc Natl
Acad Sci USA. 93:7149–7153. 1996.PubMed/NCBI
|
|
5
|
van Baren N, Chambost H, Ferrant A, et al:
PRAME, a gene encoding an antigen recognized on a human melanoma by
cytolytic T cells, is expressed in acute leukaemia cells. Br J
Haematol. 102:1376–1379. 1998.PubMed/NCBI
|
|
6
|
Chen YT, Boyer AD, Viars CS, Tsang S, Old
LJ and Arden KC: Genomic cloning and localization of CTAG, a gene
encoding an autoimmunogenic cancer-testis antigen NY-ESO-1, to
human chromosome Xq28. Cytogenet Cell Genet. 79:237–240. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gure AO, Türeci O, Sahin U, et al: SSX: a
multigene family with several members transcribed in normal testis
and human cancer. Int J Cancer. 72:965–971. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Almstedt M, Blagitko-Dorfs N, Duque-Afonso
J, et al: The DNA demethylating agent 5-aza-2′-deoxycytidine
induces expression of NY-ESO-1 and other cancer/testis antigens in
myeloid leukemia cells. Leuk Res. 34:899–905. 2010.
|
|
9
|
Hunder NN, Wallen H, Cao J, et al:
Treatment of metastatic melanoma with autologous CD4+ T
cells against NY-ESO-1. N Engl J Med. 358:2698–2703. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fradet Y, Picard V, Bergeron A and LaRue
H: Cancer-testis antigen expression in bladder cancer. Prog Urol.
15(Suppl 1): 1303–1313. 2005.PubMed/NCBI
|
|
11
|
Calabrò L, Fonsatti E, Altomonte M, et al:
Methylation-regulated expression of cancer testis antigens in
primary effusion lymphoma: immunotherapeutic implications. J Cell
Physiol. 202:474–477. 2005.PubMed/NCBI
|
|
12
|
Wang PJ, McCarrey JR, Yang F and Page DC:
An abundance of X-linked genes expressed in spermatogonia. Nat
Genet. 27:422–426. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Takano K, Miki T, Katahira J and Yoneda Y:
NXF2 is involved in cytoplasmic mRNA dynamics through interactions
with motor proteins. Nucleic Acids Res. 35:2513–2521. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen CP, Su YN, Lin HH, et al: De novo
duplication of Xq22.1→q24 with a disruption of the NXF gene cluster
in a mentally retarded woman with short stature and premature
ovarian failure. Taiwan J Obstet Gynecol. 50:339–344.
2011.PubMed/NCBI
|
|
15
|
Pan J, Eckardt S, Leu NA, et al:
Inactivation of Nxf2 causes defects in male meiosis and
age-dependent depletion of spermatogonia. Dev Biol. 330:167–174.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Stouffs K, Tournaye H, Van der Elst J,
Liebaers I and Lissens W: Is there a role for the nuclear export
factor 2 gene in male infertility? Fertil Steril. 90:1787–1791.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen YT, Ross DS, Chiu R, et al: Multiple
cancer/testis antigens are preferentially expressed in
hormone-receptor negative and high-grade breast cancers. PLoS One.
6:e178762011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dubovsky JA, McNeel DG, Powers JJ, Gordon
J, Sotomayor EM and Pinilla-Ibarz JA: Treatment of chronic
lymphocytic leukemia with a hypomethylating agent induces
expression of NXF2, an immunogenic cancer testis antigen. Clin
Cancer Res. 15:3406–3415. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jaatinen T and Laine J: Isolation of
mononuclear cells from human cord blood by Ficoll-Paque density
gradient. Curr Protoc Stem Cell Biol. Chapter 2(Unit
2A.1)2007.PubMed/NCBI
|
|
20
|
Lübbert M, Ruter BH, Claus R, et al: A
multicenter phase II trial of decitabine as first-line treatment
for older patients with acute myeloid leukemia judged unfit for
induction chemotherapy. Haematologica. 97:393–401. 2012.PubMed/NCBI
|
|
21
|
van Dongen JJ, Macintyre EA, Gabert JA, et
al: Standardized RT-PCR analysis of fusion gene transcripts from
chromosome aberrations in acute leukemia for detection of minimal
residual disease. Report of the BIOMED-1 Concerted Action:
investigation of minimal residual disease in acute leukemia.
Leukemia. 13:1901–1928. 1999.
|
|
22
|
Li CS, Chen C, Zheng P and Liu Y:
Transgenic expression of P1A induced thymic tumor: a role for
onco-fetal antigens in tumorigenesis. PLoS One. 5:e134392010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li LC and Dahiya R: MethPrimer: designing
primers for methylation PCRs. Bioinformatics. 18:1427–1431. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Quintarelli C, Dotti G, Hasan ST, et al:
High-avidity cytotoxic T lymphocytes specific for a new
PRAME-derived peptide can target leukemic and leukemic-precursor
cells. Blood. 117:3353–3362. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yan M, Himoudi N, Basu BP, et al:
Increased PRAME antigen-specific killing of malignant cell lines by
low avidity CTL clones, following treatment with
5-aza-2′-deoxycytidine. Cancer Immunol Immunother. 60:1243–1255.
2011.PubMed/NCBI
|
